News
The most recent news and industry headlines are presented in this section. Our dedicated team closely observes the pharmaceutical industry and keeps you informed of the most recent developments around the Europe.
EpiVario Finalizes Acquisition of ACSS2 Inhibitor Portfolio from Metabomed LTD
Wednesday, January 17, 2024EpiVario Inc a leading biotechnology company specializing in neuroepigenetics for the treatment of addiction disorders has recently finalized an asset purchase agreement with Metabomed LTD This agreement involves the acquisition of Metabomeds portfol...
Accurus Biosciences and ImmPACT Bio Establish Exclusive Global Licensing Agreement for a Promising CLDN18.2 Antibody with Potential Best-in-Class Attributes
Wednesday, January 17, 2024Accurus Biosciences Inc is delighted to announce the initiation of a global licensing agreement for its CLDN monoclonal antibody with ImmPACT Bio USA Inc a clinicalstage company dedicated to advancing nextgeneration
Andelyn Biosciences, Armatus Bio Partner for CMT1A Gene Therapy
Tuesday, January 16, 2024Andelyn Biosciences Inc a prominent Contract Development and Manufacturing Organization specializing in cell and gene therapy has formed a strategic partnership with Armatus Bio to expedite the manufacturing process for their gene therapy
PharmAlliance Finalizes Purchase of Monitor for Hire
Friday, January 12, 2024PharmAlliance a diversified pharmaceutical and life sciences services provider is excited to announce its recent acquisition of Monitorforhire a robust business recognized for its online system that connects clinical research monitors
Fortrea Collaborates With Veeva and Advarra to Improve Patient and Site Experiences in Clinical Trials
Thursday, January 11, 2024Fortrea has recently announced a strategic industry collaboration with key partners Veeva Systems Inc and Advarra forming a leading global contract research organization Veeva a major provider of cloud solutions
Ariceum Therapeutics Initiates Application for UK Clinical Trial Authorization to Evaluate First-of-its-Kind Iodine-123 Labeled PARP Inhibitor in Patients with Recurrent Glioblastoma
Thursday, January 11, 2024Ariceum Therapeutics a private biotech company focused on developing radiopharmaceutical products for challenging cancers has officially submitted an application to the UKs Medicines and Healthcare products Regulatory Agency
GBI Enhances Its Position in Radiopharmaceutical Manufacturing Through the Acquisition of a New Contract for Commercial Manufacturing
Wednesday, January 10, 2024GBI BioManufacturing formerly recognized as Goodwin Biotechnology is excited to announce the completion of its second master supply agreement for the commercialization of a radioimmunoconjugate product
Constant Therapeutics Commences Phase 2 Clinical Trial for TXA127 in Ischemic Stroke Recovery with First Patient Dosed
Wednesday, January 10, 2024Constant Therapeutics LLC a biopharmaceutical firm specializing in treatments affecting the Alternative ReninAngiotensin System has commenced its phase clinical trial for TXA This is the companys
Medison Pharma and Regeneron Pharmaceuticals Have Signed an Agreement for the Commercialization of Libtayo® (Cemiplimab) in Various Countries
Tuesday, January 09, 2024Medison Pharma a global pharmaceutical company dedicated to providing access to innovative therapies internationally recently announced an exclusive multinational agreement with Regeneron Ireland DAC
Debiopharm Extends Collaboration with SunRock Biopharma for Antibody-Drug Conjugates Targeting HER3 in EGFR-Mutated Cancers
Tuesday, January 09, 2024Debiopharm a Swiss biopharmaceutical company specializing in cancer and infectious disease treatments has secured an option for an exclusive licensing agreement with SunRock Biopharma SunRock Biopharma
